Vetting a 503B Outsourcing Facility Before You Order

A hospital, infusion clinic, or physician practice that orders compounded sterile preparations from a 503B outsourcing facility is buying from a facility it does not control. When FDA cites that facility on a Form 483 or warning letter, or when a lot is recalled, the purchasing practice is the one holding the affected inventory, notifying patients, and explaining the vendor relationship to its own state board or accrediting body. A documented vetting file, built before the first order ships, is the purchaser's clearest way to limit that exposure.

FDA Registration and State Licensure

Confirm the facility is currently registered as an outsourcing facility under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act, not merely a state-licensed compounding pharmacy operating under the narrower 503A pathway. FDA registration is not the whole answer: in nearly every state, an outsourcing facility must also hold a separate nonresident outsourcing facility, manufacturer, or wholesaler permit from the state board of pharmacy before it may lawfully ship into that state. Confirm the license covering the state where the preparation will be received, not just the facility's home-state credentials, and ask for current registration and license numbers rather than relying on marketing material that may lag a lapse or suspension.

Inspection History, Form 483s, and Warning Letters

Outsourcing facilities are inspected on a risk-based schedule and are measured against cGMP requirements under 21 CFR Parts 210 and 211, the same framework FDA applies to conventional drug manufacturers and a materially higher bar than the state board and USP 797/800 standards that govern most 503A compounding pharmacies. FDA publishes every Form 483 observation and warning letter tied to a named facility, and a purchaser should pull both before ordering. Read the observations for substance, not count: two open sterility or environmental-monitoring findings carry different risk than two closed, corrected labeling findings from a single visit.

Recall History and What the Facility May Lawfully Compound

Search FDA's Enforcement Reports for any recall tied to the facility, and note the classification, a Class I recall involving reasonable probability of serious harm is a different signal than a Class III labeling recall. Two further limits define what the facility may lawfully compound at all. A 503B facility generally cannot compound a preparation that is essentially a copy of an FDA-approved, commercially available drug, same active ingredient, strength, dosage form, and route of administration, absent a documented shortage. FDA has also proposed, but not yet finalized, a list of drug products presenting demonstrable compounding difficulties, covering certain modified-release oral solids, liposomal products, and hot-melt-extrusion products; once final, a facility could not lawfully compound a listed product. An order that duplicates a commercially available drug, with no shortage basis on file, is one the facility should not be filling.

Contract Terms on Indemnity, Specifications, and NDC Assignment

The purchase agreement should state which party bears the cost of a recall, a patient claim, or a state board inquiry tied to a defective preparation, rather than leaving indemnity to be argued after the fact. It should require the facility to hold to the product specifications, strength, sterility testing, and beyond-use date the purchaser actually ordered, since Beyond-Use Dating: Where Compounders Get Cited is among the most common inspection findings. And it should confirm the facility assigns a usable National Drug Code for each preparation, since Billing and NDC Assignment for Compounded Preparations covers how a missing or mismatched code exposes the purchasing practice's own billing, not the facility's.

The purchasing practice, not the outsourcing facility, is usually the one a state board, a payor, or a CMS contractor asks to explain why a recalled or non-compliant preparation reached a patient.

Why Early Legal Counsel Is Critical

It is critical that healthcare practices retain experienced healthcare defense counsel before finalizing a 503B outsourcing facility contract, and immediately if a preparation already in inventory is later tied to a warning letter, a Form 483 finding, or a recall. Early legal review can negotiate indemnification and specification language that allocates liability to the facility rather than the purchaser, document the vetting file a state board or payor will later ask to see, and respond to an inquiry before it hardens into a referral against the practice. Waiting until a recall notice arrives leaves the practice negotiating after the preparation is already dispensed.

How Health Law Alliance Can Help

Health Law Alliance has handled 5,000+ matters across healthcare regulatory and audit defense over 25+ years, including outsourcing facility vetting, purchase agreement review, and defense of practices caught in a supplier's recall or citation. If your practice is negotiating a 503B supply relationship or has received a notice tied to a compounded preparation you purchased, contact Health Law Alliance's compounding pharmacy defense attorneys for a free, confidential consultation.